Navigating through novelties concerning mCRC treatment-the role of immunotherapy, chemotherapy, and targeted therapy in mCRC.

Autor:	Zheng E; Department of General and Oncological Surgery, Faculty of Medicine, Medical University of Lodz, Lodz, Poland., Włodarczyk M; Department of General and Oncological Surgery, Faculty of Medicine, Medical University of Lodz, Lodz, Poland., Węgiel A; Department of General and Oncological Surgery, Faculty of Medicine, Medical University of Lodz, Lodz, Poland., Osielczak A; Department of General and Oncological Surgery, Faculty of Medicine, Medical University of Lodz, Lodz, Poland., Możdżan M; Department of General and Oncological Surgery, Faculty of Medicine, Medical University of Lodz, Lodz, Poland., Biskup L; Department of General and Oncological Surgery, Faculty of Medicine, Medical University of Lodz, Lodz, Poland., Grochowska A; Department of General and Oncological Surgery, Faculty of Medicine, Medical University of Lodz, Lodz, Poland., Wołyniak M; Department of General and Oncological Surgery, Faculty of Medicine, Medical University of Lodz, Lodz, Poland.; Department of Biostatistics and Translational Medicine, Medical University of Lodz, Lodz, Poland., Gajewski D; Department of General and Oncological Surgery, Faculty of Medicine, Medical University of Lodz, Lodz, Poland., Porc M; Department of General and Oncological Surgery, Faculty of Medicine, Medical University of Lodz, Lodz, Poland., Maryńczak K; Department of General and Oncological Surgery, Faculty of Medicine, Medical University of Lodz, Lodz, Poland., Dziki Ł; Department of General and Oncological Surgery, Faculty of Medicine, Medical University of Lodz, Lodz, Poland.
Jazyk:	angličtina
Zdroj:	Frontiers in surgery [Front Surg] 2024 Jun 14; Vol. 11, pp. 1398289. Date of Electronic Publication: 2024 Jun 14 (Print Publication: 2024).
DOI:	10.3389/fsurg.2024.1398289
Abstrakt:	Over the course of nearly six decades since the inception of initial trials involving 5-FU in the treatment of mCRC (metastatic colorectal cancer), our progressive comprehension of the pathophysiology, genetics, and surgical techniques related to mCRC has paved the way for the introduction of novel therapeutic modalities. These advancements not only have augmented the overall survival but have also positively impacted the quality of life (QoL) for affected individuals. Despite the remarkable progress made in the last two decades in the development of chemotherapy, immunotherapy, and target therapies, mCRC remains an incurable disease, with a 5-year survival rate of 14%. In this comprehensive review, our primary goal is to present an overview of mCRC treatment methods following the latest guidelines provided by the National Comprehensive Cancer Network (NCCN), the American Society of Clinical Oncology (ASCO), and the American Society of Colon and Rectal Surgeons (ASCRS). Emphasis has been placed on outlining treatment approaches encompassing chemotherapy, immunotherapy, targeted therapy, and surgery's role in managing mCRC. Furthermore, our review delves into prospective avenues for developing new therapies, offering a glimpse into the future of alternative pathways that hold potential for advancing the field. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (© 2024 Zheng, Włodarczyk, Węgiel, Osielczak, Możdżan, Biskup, Grochowska, Wołyniak, Gajewski, Porc, Maryńczak and Dziki.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu